The group has received the Food and Drug Administration (FDA) approval to market 10, 20, 40, 80 mg of Pravastatin Sodium tablets in the United States, Cadila Healthcare said in a filing to the Bombay Stock Exchange.
Cadila has also received tentative approval from the regulatory body to market Escitalopram Oxalate tablets (5, 10 and 20 mg), Losartam Potassium and Hydrochlorthiazide tablets (50mg/12.5 mg and 100 mg/25 mg) and Anastrazole tablets (1 mg) in the US, the filing said.
The US market of lipid lowering agent Pravastatin Sodium tablet was estimated at 1.9 million dollar in 2007, while the branded sales of anti-depressant Escitalopram Oxalate tablets was at $3 billion.
In 2007, the sale of anti-hypertensive Losartam Potassium and Hydrochlorthiazide tablets stood at $785 million, while Anastrazole tablets had a market of $813 million, the filling added.